(Q40201466)

18 September 2017

HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target (English)

1 reference

18 September 2017

1 reference

lymphoblastic leukemia

1 reference

14

Hagop M Kantarjian

1 reference

18 September 2017

Guillermo Garcia-Manero

2

object named as

Guillermo Garcia-Manero

1 reference

18 September 2017

6

Lianchun Xiao

1 reference

18 September 2017

15

Carlos E Bueso-Ramos

1 reference

18 September 2017

7

Gary Rosner

1 reference

18 September 2017

5

L Jeffrey Medeiros

1 reference

18 September 2017

9

Michael Fernandez

1 reference

18 September 2017

Allison Martin Nguyen

8

object named as

Martin Nguyen

1 reference

18 September 2017

Xin Han

1

1 reference

18 September 2017

Timothy J McDonnell

3

1 reference

18 September 2017

Guillermina Lozano

4

1 reference

18 September 2017

Yasmine A Valentin-Vega

10

1 reference

18 September 2017

Juan Barboza

11

1 reference

18 September 2017

Daniel M Jones

12

1 reference

18 September 2017

Georgios Z Rassidakis

13

1 reference

18 September 2017

24 November 2006

1 reference

18 September 2017

1 reference

18 September 2017

20

1 reference

18 September 2017

54-62

1 reference

18 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.3800727

18 September 2017

0 references

cites work

Mdmx as an essential regulator of p53 activity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Mutual dependence of MDM2 and MDMX in their functional inactivation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

BCR/ABL activates mdm2 mRNA translation via the La antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

7 January 2021

TP53is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

7 January 2021

Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800727

7 January 2021

10.1038/MODPATHOL.3800727

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

0 references

1 reference